ArticleBMC gastroenterology2025
Resveratrol mitigates aspirin-induced intestinal injury in rats in a high-altitude hypoxic environment associated with reducing the expression levels of angiotensin II.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThis study aimed to investigate whether the polyphenolic compound resveratrol can protect against intestinal injury induced by aspirin in hypoxic rats associated with the inhibition of angiotensin II (Ang-II), as well as mitigating intestinal mucosal oxidative stress and inflammation.
methodThe plain control group rats received daily gavage in a conventional atmosphere, while the high-altitude blank control group rats underwent the same procedure but was housed in a chamber simulating the hypoxic environment in a high-altitude.while the remaining groups rats were also housed in this hypoxic chamber and received daily aspirin gavage to establish an Aspirin-induced intestinal injury model. The resveratrol intervention group was administered resveratrol at varying doses 2 h post-aspirin gavage. Small intestinal mucosal gross morphology and histopathological damage were observed and scored across all groups. ELISA quantified MPO and SOD activity and IL-1β, IL-10, TNF-α levels in intestinal tissues, while immunohistochemistry assessed Ang-II and Intercellular adhesion molecule-1 (ICAM-1) expression.
resultThe high-altitude blank control group rats not only showed substantial intestinal injuries but also exhibited elevated expression of Ang-II and ICAM-1 in the small intestinal tissues of rats, which positively correlated with the degree of histological injury to the mucosa. Furthermore, there was increased expression of pro-inflammatory factors IL-1β and TNF-α, decreased expression of the anti-inflammatory factor IL-10, and elevated levels of the oxidative stress indicator myeloperoxidase (MPO) activity, while the levels of superoxide dismutase (SOD) were decreased in the small intestinal tissues of rats. The administration of aspirin in the hypoxic environment exacerbated intestinal inflammation and damage to the intestinal mucosa. After treatment with Resveratrol intervention, the expression of Ang-II and ICAM-1 was reduced, while oxidative stress and inflammatory responses in the intestinal mucosa were also decreased. The results of HE staining directly demonstrated the damage to the intestines and the repair of the intestinal mucosa after Resveratrol intervention. The effect of medium-dose resveratrol appeared to be particularly pronounced.
conclusionResveratrol can effectively mitigate intestinal injury induced by aspirin at high altitude in hypoxic environments. The mechanism may involve downregulating the expression of Ang-II and ICAM-1, alleviating oxidative stress and the inflammatory response of the intestinal mucosa, and preserving intestinal barrier function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.